LEI 5299001JXIQ2V7N0ZD85

Boehringer Ingelheim Pharma GmbH & Co. KG

Group parent: C.H. Boehringer Sohn AG & Co. KG

Awards tracked

16

Value

€1.26M

Countries

DE

Download sample CSV

Contract awards & public grants

Doctoral network on discovering pathomechanisms and novel drug optimization for AMD → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2026-07-01

—

FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2026-06-02

—

Lipids as promising BRidge between novel disease InsiGHts and improved Therapy → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2025-07-11

—

Doctoral Network on Interfacial Water in Membrane Transport → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2025-06-23

€290,272

Propelling the shift toward the future of circular, safe and sustainable packaging and single use device ecoDesigned solutions through healthcare envi → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2024-12-18

—

Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2024-12-12

—

Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2024-12-05

—

Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2024-11-12

—

Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2024-07-26

—

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition. → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2019-08-19

€252,788

Proton transport and proton-coupled transport → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2019-08-09

€252,788

ENdoThelial macRophage Alliance In Neuroinflammation → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2019-05-07

—

Interdisciplinary training network for advancing Organ-on-a-chip technology in Europe → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2018-08-21

—

Thrombo-inflammation in cardiovascular disease → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2018-08-20

—

Big Data in Chemistry → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2015-07-27

€463,820

Enhancing CHO by Mammalian Systems Biotechnology (eCHO systems) → BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

European Commission · DE · Grant · 2014-12-05

—

Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.